MedTrace Logo

Influence of Glucose on Metabolism and Clinical Symptoms of Patients With Parkinson's Disease

NCT05998772 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-09-22

No results posted yet for this study

Summary

Many patients with Parkinson's Disease (PD) report an increased consumption of fast-acting sugars. This tendency to consume sweet, high-sugar foods occurs in some patients even before the onset of cardinal motor symptoms. Some recent studies have demonstrated that PD patients have an increased consumption of fast-acting carbohydrates compared to healthy controls. However, the reason for this change in eating behavior has not yet been adequately explained. It is discussed that the increased sugar intake leads to an increased dopamine release in the brain via an increase in insulin and thus to an improvement in clinical symptoms. This study investigates the influence of fast-acting carbohydrates on insulin and glucose blood levels as well as motor and non-motor symptoms in patients with PD using an oral glucose tolerance test and a placebo oral glucose tolerance test in a crossover design.

Conditions

  • Parkinson Disease
  • Nutritional and Metabolic Diseases
  • Sugar Intake

Interventions

DIAGNOSTIC_TEST

Oral Glucose Tolerance Test

Application of 82,5 g of glucose monohydrate solved in 300ml water

OTHER

Placebo Oral Glucose Tolerance Test

Application of 125mg sucralose solved in 300ml water

Sponsors & Collaborators

  • University of Kiel

    collaborator OTHER

  • University Hospital Schleswig-Holstein

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05998772 on ClinicalTrials.gov